<DOC>
	<DOCNO>NCT00922597</DOCNO>
	<brief_summary>The objective international post-marketing surveillance study collect data efficacy safety continuous infusion KOGENATE Bayer surgery .</brief_summary>
	<brief_title>Non-interventional Observation Practical Implementation , Efficacy Safety Continuous Infusion With KOGENATE Bayer Surgery</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Inpatients diagnosis severe haemophilia A ( FVIII &lt; 1 % ) , heavily pretreated ( &gt; 150 exposure day ) , without history inhibitor , negative inhibitor test available , decision take investigator administer KOGENATE Bayer via continuous infusion surgery .</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Continuous infusion</keyword>
	<keyword>Surgery</keyword>
	<keyword>Severe haemophilia A</keyword>
</DOC>